Date: 2012-10-09
Type of information: R&D agreement
Compound: specific small molecule lead candidates for a novel exploratory target chosen by Servier
Company: NovAliX (France) Servier (France)
Therapeutic area: undisclosed
Type agreement: R&D
services
Action mechanism:
Disease: undisclosed
Details: NovAliX has entered into drug discovery collaboration with the pharmaceutical company Servier. Under the terms of this agreement Graffinity, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier. NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound protein interactions. NovAliX will receive technology access fees and research funding from Servier.
Financial terms:
Latest news:
